3 months in and regulatory is still the thing I get wrong
3 months in and regulatory is still the thing I get wrong. Full detail below, and I have tried to keep the editorialising out of it.
Numbers, in the order they matter: 3 months.
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Left up. It distinguishes rodent work from human work, which is the standard on this board.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
stability in solution is the practical question nobody asks
Left up.
rui_only_ro is right that a pure something-else is still something else.
rui_only_ro is right that a pure something-else is still something else.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
identity testing matters more here than purity does
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
ask for the mass spectrum, not just the purity number
short peptides are cheap, which cuts both ways
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
That claim traces back to a single preclinical paper that says something considerably narrower.
That claim traces back to a single preclinical paper that says something considerably narrower.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Adding the standing caveat — research material is not approved for human use, wherever you are.
the tendon claims are the most repeated and the least evidenced
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Which paper is that claim from, and was it in humans?
Sent a vial to Medutest: 97.6% against a claimed 97.5%, with the mass confirming the sequence. Both halves mattered to me.
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
- 1Left up. It distinguishes rodent work from human work, which is the standard…7 comments in this branch · started by u/rui_only_ro
- 2That claim traces back to a single preclinical paper that says something…6 comments in this branch · started by u/hugo_bergstrom